Emergent BioSolutions (EBS) Stock

GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD).

An analyst started following Emergent BioSolutions (NYSE: EBS) stock as the final trading week of 2024 began, and investors responded favorably. H.C. Wainwright's Raghuram Selvaraju is now monitoring Emergent, which has a broad range of revenue sources. Selvaraju suggests that Emergent is well-diversified and operates in various medical areas with strong growth potential.

An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.

The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.

Emergent BioSolutions (NYSE: EBS) experienced a drop in its stock price on Tuesday following reports of a share sell-off. The sellers are primarily linked to OHA Agency, which gave Emergent a $250 million loan in August. Emergent clarified in its statement that it will not benefit financially from these sales, as it is not involved in the selling process.

Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities.

Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats.

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago.